Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock – Jan 20, 2021
The Pharma Data
JANUARY 19, 2021
Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The Company anticipates that subsequent events and developments will cause the Company’s views to change. Forward-Looking Statements.
Let's personalize your content